Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease
- 24 March 2003
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 53 (S3) , S149-S159
- https://doi.org/10.1002/ana.10514
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studiesAnnals of Neurology, 2003
- Oxidative stress in Parkinson's diseaseAnnals of Neurology, 2003
- Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2000
- Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐hydroxydopamineMovement Disorders, 1998
- Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexoleJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1997
- Inhibitory Effects of Talipexole and Pramipexole on MPTP-Induced Dopamine Reduction in the Striatum of C57BL/6N Mice.The Japanese Journal of Pharmacology, 1997
- Intense oxidative DNA damage promoted by l‐DOPA and its metabolites implications for neurodegenerative diseaseFEBS Letters, 1994
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's diseaseMovement Disorders, 1994
- Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 ratsNeurobiology of Aging, 1992